Insulin receptor mRNA in the substantia nigra in Parkinson's disease

Neurotrophic effects resulting from the insulin/insulin receptor system have been recognized as important in determining the etiological basis of neurodegenerative disorders. In Parkinson's disease, selective neuronal loss in the substantia nigra is accompanied by decreased immunoreactivity of the insulin receptor as determined using immunohistochemical studies. We performed semiquantitative mRNA analysis by reverse transcription-polymerase chain reaction (RT-PCR) using specific primers for human insulin receptor exon 22, which encodes a region of the beta subunit of the receptor serving as a tyrosine kinase domain. The relative levels of mRNA in the substantia nigra from Parkinson's brain tissues showed a marked depression compared with those of normal controls. Further investigations are needed to decide whether this is a primary, disease-specific alteration of gene expression or merely a secondary process.

[1]  J. Mallet,et al.  A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics , 1987, Nature.

[2]  S. Gammeltoft,et al.  Insulin receptors in the mammalian central nervous system: binding characteristics and subunit structure. , 1985, Biochimie.

[3]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[4]  S. Varon,et al.  Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  H. Bradford,et al.  The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment , 1994, Brain Research.

[6]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[7]  K. Unsicker,et al.  Transforming growth factor-beta promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity. , 1994, Neuroscience.

[8]  K. Unsicker.  Growth factors in Parkinson's disease. , 1994, Progress in growth factor research.

[9]  J. Sutcliffe,et al.  p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. , 1988, DNA.

[10]  H. Kimura,et al.  Demonstration of fibroblast growth factor receptor‐I in human prostate by polymerase chain reaction and immunohistochemistry , 1995, The Prostate.

[11]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[12]  S. Seino,et al.  Human Insulin-Receptor Gene , 1990, Diabetes.

[13]  P. H. Seeburg,et al.  Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes , 1985, Nature.

[14]  K. Jarnagin,et al.  The human insulin receptor cDNA: The structural basis for hormone-activated transmembrane signalling , 1985, Cell.

[15]  H. Yokoi,et al.  Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. , 1992, Nucleic acids research.

[16]  J. Olefsky.  The Insulin Receptor: A Multifunctional Protein , 1990, Diabetes.

[17]  D. Gelfand,et al.  1 – OPTIMIZATION OF PCRs , 1990 .

[18]  H. Kimura,et al.  Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease , 1993, Neurology.

[19]  B. Haendler,et al.  Complementary DNA for human T‐cell cyclophilin. , 1987, The EMBO journal.